To truly attain effective and safe pharmacotherapy, the similarities and dissimilarities in
physiology between micro-preemies and extreme preterm infants should be explored. The …

In premature infants, effective and safe drug therapy depends on optimal dose selection and
requires a thorough understanding of the underlying disease (s) of these fragile infants as …

The lack of adequate dosing regimens mostly due to off-label use and the high
interindividual variability in both pharmacokinetics (PK) and pharmacodynamics (PD) make …

Drug dosing in infants should be based on their physiological characteristics and the
pharmacokinetic and-dynamic profile of the compound. Since maturational physiological …

Background Developmental physiology can alter pharmacotherapy in preterm populations.
Because of ethical and clinical constraints in studying this vulnerable age group …

Drug therapy is a powerful tool for improving neonatal outcome. Despite this, neonatologists
still routinely prescribe off-label compounds developed for adults and extrapolate doses …

Pharmacologic study is needed in the extremely immature newborns who currently survive.
Study is needed of both the drug treatment previously established in more mature neonates …

During the neonatal period, there is physiological immaturity of organs, systems and
metabolic pathways that influences the pharmacokinetics and pharmacodynamics of …

Carefully vetted dosing recommendations for the majority of drugs used in the neonatal
intensive care unit are currently lacking, partly because they have not been submitted to the …

Neonates are a uniquely vulnerable population, compromised by immature physiology and
critical illness if born premature. Furthermore, neonates have frequent exposures to drugs …